The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.
The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.
The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.
"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.
Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.
The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.
Most Popular Stories
- Small-Business Loans Fueling Economic Growth
- Tesco Head Steps Down After Profit Warning
- Comic-Con Offers Toy Designers a Chance to Go Wild
- Want a Job? Try Minneapolis
- Google Chrome Bug Draining Batteries: Report
- Clinton Wants U.S., E.U. to Get Tough on Russia
- Startup Makes It Easier to Buy American
- BlackBerry Appoints New COO from LiveOps Inc.
- GM Looking for Ignition Fix for Certain Cadillacs
- U.S. Stocks Start the Week on Shaky Ground